Takeda Leads Uncluttered Race For First Norovirus Therapy
Although norovirus infections are implicated in roughly 200,000 deaths per year, there are only four candidates in clinical development, Datamonitor Healthcare notes. This may be due partly to challenges posed by the virus' strain diversity and a lack of epidemiologic data.
You may also be interested in...
Takeda has initiated dosing in the first field trial globally with a candidate vaccine for norovirus, maintaining its clear development lead in the area.
Strong top-line efficacy in pyruvate kinase deficiency patients who don’t receive regular transfusions looks approvable, analysts say, but Agios will await data in regularly transfused patients.
With its US/Mexico Phase III trial delayed due to manufacturing questions, Novavax has aligned its UK study with FDA guidance. It hopes for interim data from that study during Q1 2021.